Cantor Fitzgerald Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $35

Cantor Fitzgerald maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $27 to $35.

Benzinga · 01/27/2020 12:35

Cantor Fitzgerald maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $27 to $35.